<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Incyte Corporation — News on 6ix</title>
<link>https://6ix.com/company/incyte-corporation</link>
<description>Latest news and press releases for Incyte Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/incyte-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583ba78dffbe2df0fcd03.webp</url>
<title>Incyte Corporation</title>
<link>https://6ix.com/company/incyte-corporation</link>
</image>
<item>
<title>Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-reports-first-quarter-2026-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-reports-first-quarter-2026-financial-results-and-provides-business-updates</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>WILMINGTON, Del., April 28, 2026--Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates</description>
</item>
<item>
<title>Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)</title>
<link>https://6ix.com/company/incyte-corporation/news/adagene-announces-clinical-collaboration-with-incyte-to-evaluate-muzastotug-adg126-in-combination-with-incytes-tgfssr2xpd-1-bispecific-antibody-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer-mss-crc-6</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/adagene-announces-clinical-collaboration-with-incyte-to-evaluate-muzastotug-adg126-in-combination-with-incytes-tgfssr2xpd-1-bispecific-antibody-inca33890-in-patients-with-microsatellite-stable-colorectal-cancer-mss-crc-6</guid>
<pubDate>Thu, 02 Apr 2026 11:01:00 GMT</pubDate>
<description>Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration provides additional validation of muzastotug as a potential backbone therapy for next-generation immuno-oncology combinations SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the disco</description>
</item>
<item>
<title>Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-announces-new-positive-54-week-late-breaking-data-for-povorcitinib-in-hidradenitis-suppurativa-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-announces-new-positive-54-week-late-breaking-data-for-povorcitinib-in-hidradenitis-suppurativa-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to</description>
</item>
<item>
<title>Incyte Announces Executive Leadership Appointments</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-announces-executive-leadership-appointments</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-announces-executive-leadership-appointments</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic</description>
</item>
<item>
<title>Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-to-highlight-late-breaking-hidradenitis-suppurativa-data-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-to-highlight-late-breaking-hidradenitis-suppurativa-data-at-the-2026-american-academy-of-dermatology-aad-annual-meeting</guid>
<pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
<description>- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib</description>
</item>
<item>
<title>Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-announces-the-european-commission-approval-of-zynyzr-retifanlimab-for-the-first-line-treatment-of-advanced-squamous-cell-carcinoma-of-the-anal-canal-scac-3</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-announces-the-european-commission-approval-of-zynyzr-retifanlimab-for-the-first-line-treatment-of-advanced-squamous-cell-carcinoma-of-the-anal-canal-scac-3</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with</description>
</item>
<item>
<title>Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata</title>
<link>https://6ix.com/company/incyte-corporation/news/lillys-olumiant-baricitinib-recommended-by-chmp-for-approval-of-expanded-use-in-the-european-union-for-adolescents-with-severe-alopecia-areata-1</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/lillys-olumiant-baricitinib-recommended-by-chmp-for-approval-of-expanded-use-in-the-european-union-for-adolescents-with-severe-alopecia-areata-1</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more</description>
</item>
<item>
<title>Incyte Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-reports-fourth-quarter-full-120000756</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-reports-fourth-quarter-full-120000756</guid>
<pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
<description>WILMINGTON, Del., February 10, 2026--Incyte Reports Fourth Quarter and Full Year 2025 Financial Results</description>
</item>
<item>
<title>Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-announces-positive-chmp-opinion-zynyzr-retifanlimab-first-line-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-announces-positive-chmp-opinion-zynyzr-retifanlimab-first-line-treatment</guid>
<pubDate>Fri, 30 Jan 2026 05:00:00 GMT</pubDate>
<description>Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the</description>
</item>
<item>
<title>Incyte to Report Fourth Quarter and Year-End 2025 Financial Results</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-report-fourth-quarter-and-year-end-2025-financial-results-2026-01-27</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-report-fourth-quarter-and-year-end-2025-financial-results-2026-01-27</guid>
<pubDate>Tue, 27 Jan 2026 05:00:00 GMT</pubDate>
<description>WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results</description>
</item>
<item>
<title>Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-announces-positive-topline-results-pivotal-study-tafasitamab-monjuvir-minjuvir</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-announces-positive-topline-results-pivotal-study-tafasitamab-monjuvir-minjuvir</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary</description>
</item>
<item>
<title>Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-japan-announces-approval-minjuvir-tafasitamab-combination-rituximab-and</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-japan-announces-approval-minjuvir-tafasitamab-combination-rituximab-and</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>TOKYO--(BUSINESS WIRE)-- Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi®</description>
</item>
<item>
<title>Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-japan-announces-approval-zynyzr-retifanlimab-first-line-treatment-advanced</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-japan-announces-approval-zynyzr-retifanlimab-first-line-treatment-advanced</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>TOKYO--(BUSINESS WIRE)-- Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz®</description>
</item>
<item>
<title>Incyte to Present at Upcoming Investor Conference</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-present-upcoming-investor-conference-2025-12-18</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-present-upcoming-investor-conference-2025-12-18</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on</description>
</item>
<item>
<title>Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-announces-european-commission-approval-minjuvir-tafasitamab-treatment-relapsed</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-announces-european-commission-approval-minjuvir-tafasitamab-treatment-relapsed</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab is the first CD19- and CD20-dual-targeted immunotherapy combination regimen approved</description>
</item>
<item>
<title>Incyte Announces Change to its Board of Directors</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-announces-change-its-board-directors-2025-12-12</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-announces-change-its-board-directors-2025-12-12</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced the resignation of Hervé Hoppenot from the Company’s Board of Directors, effective</description>
</item>
<item>
<title>Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-presents-updated-positive-data-ash-2025-reinforcing-potential-inca033989-its</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-presents-updated-positive-data-ash-2025-reinforcing-potential-inca033989-its</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>Nearly all (90%) of essential thrombocythemia (ET) patients treated with INCA033989 at the higher dose achieved a hematologic response (HR) with 83.3%</description>
</item>
<item>
<title>Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-announces-new-positive-data-inca033989-its-first-class-mutcalr-targeted</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-announces-new-positive-data-inca033989-its-first-class-mutcalr-targeted</guid>
<pubDate>Sun, 07 Dec 2025 05:00:00 GMT</pubDate>
<description>Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with</description>
</item>
<item>
<title>Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA</title>
<link>https://6ix.com/company/incyte-corporation/news/incytes-first-class-mutcalr-targeted-monoclonal-antibody-inca033989-granted</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incytes-first-class-mutcalr-targeted-monoclonal-antibody-inca033989-granted</guid>
<pubDate>Sun, 07 Dec 2025 05:00:00 GMT</pubDate>
<description>The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of CALR mutations in</description>
</item>
<item>
<title>Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/incyte-corporation/news/incyte-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2025-12-03</link>
<guid isPermaLink="true">https://6ix.com/company/incyte-corporation/news/incyte-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2025-12-03</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) announced today equity inducement awards grants to Richard Hoffman, Company’s new</description>
</item>
</channel>
</rss>